Viewing Study NCT05993234

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2025-12-28 @ 11:20 PM
Study NCT ID: NCT05993234
Status: RECRUITING
Last Update Posted: 2025-12-11
First Post: 2023-08-02
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HER2-positive Advanced Gastric Cancer View
None HER2-positive Gastroesophageal Junction Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HER2-positive Advanced Gastric Cancer View
None HER2-positive Gastroesophageal Junction Adenocarcinoma View
None Trastuzumab Deruxtecan View
None Conventional therapy View
None ENHERTU® View